Zentek Announces Regulatory Update for ZenGUARD(TM) Enhanced Air Filters

Zentek Ltd. is adapting its ZenGUARD™ Enhanced Air Filter commercialization strategy in Canada. Following a Health Canada request for information, the company withdrew its PMRA submission and intends to market the filters as a Class I medical device. Zentek, focused on patented technology for enhanced product performance, aims to improve HVAC filters and is developing aptamer-based technology with McMaster University.

GUELPH, ON – Zentek Ltd. (ZTEK:NASDAQ) (TSXV:ZEN), a company specializing in intellectual property technology development and commercialization, has received a communication from Health Canada regarding its ZenGUARD™ Enhanced Air Filters. The regulatory body is evaluating the classification of the filters and has requested additional information from Zentek.

Previously, Zentek had pursued registration of the ZenGUARD™ filters under the Pest Control Products Act through the Health Canada Pest Management Regulatory Agency (PMRA). However, on October 31, 2024, the company withdrew its submission to the PMRA, opting for an alternative commercialization strategy in Canada. As a result, Zentek announced on November 27, 2024, their intent to market the ZenGUARD™ Enhanced Air Filters as a Class I medical device under its existing MDEL, aligning with their surgical mask product line.

**A Look at Zentek’s Business**

Zentek, an ISO 13485:2016 certified company, is focused on the research, development, and commercialization of innovative products. The company aims to provide its commercial partners with a competitive edge by enhancing their products’ performance, safety, and sustainability.

At the heart of Zentek’s offering is ZenGUARD™, a patented technology platform that has demonstrated the ability to significantly improve the bacterial and viral filtration efficiency of surgical masks. The company is now targeting similar improvements for HVAC (heating, ventilation, and air conditioning) filters. Zentek’s production facility for ZenGUARD™ is located in Guelph, Ontario.

Furthermore, through its subsidiary, Triera Biosciences Ltd., Zentek holds a global exclusive license to an aptamer-based platform technology developed by McMaster University. This technology is being jointly developed by both Zentek and McMaster for applications in both the diagnostic and therapeutic markets.

**Important Notice:** This news release contains forward-looking statements. These statements are subject to risks and uncertainties. Zentek disclaims any obligation to update or revise forward-looking information except where required by law.

Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/3439.html

Like (0)
Previous 5 hours ago
Next 1 hour ago

Related News